The following is an excerpt from Reuters.
The European Medicines Agency (EMA) is recommending Novavax's Covid-19 vaccine carry a warning of the possibility of two types of heart inflammation, an added burden for a shot that has so far failed to win wide uptake.
- The Clot Factor: A Full Measure Town Hall
- Long Vax, Long Covid Resources
- Covid-19 Natural Immunity: The Definitive Summary
- Covid-19 Vaccine: 80 of the Most Common Adverse Events
- Covid-19 Vaccine Concerns Summary
- Covid-19 Vaccine Analysis: Common Adverse Events
- Covid-19 Origins: Separating Rumor from Fact (WATCH)
- Report a Possible Vaccine Adverse Event
The heart conditions - myocarditis and pericarditis - should be listed as new side effects in the product information for the vaccine, Nuvaxovid, based on a small number of reported cases, the EMA said on Wednesday.
Novavax (NVAX.O) said no concerns about heart inflammations were raised during the clinical trials of Nuvaxovid and that more data would be gathered, adding that the most common cause of myocarditis is viral infections.
The EMA said on Wednesday it had asked Novavax to provide additional data on the risk of these side effects.
Last month, the EU agency identified severe allergic reactions as potential side effects of the vaccine.
In June, the U.S. Food and Drug Administration flagged a risk of heart inflammation from the Novavax vaccine.
Read full article here.
Visit the Lemonade Mermaid Store today
Original and Custom items for Land or Sea Mermaids
Does the EMA require similar warnings for the older vaccines, which have had many more reports of heart inflammation than this newer vaccine?